News

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...
Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...
Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...
The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various ...
For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...
On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the ...
Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...
Merck's Q3 2023 earnings results will be announced on October 26th. In this preview, I highlight some issues to consider and news to look out for. Keytruda, Merck's immuno-oncology drug, continues ...
Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again. That prowess makes Keytruda’s recent string of failures more noteworthy.
Earlier this month, we highlighted how Keytruda is a ticking time bomb for Merck stock. In this analysis, we explore the potential upside for Merck despite its short-term hurdles.
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’ s anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medical ...
Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...